Dyanavel XR 2017 U.S. PROMOTIONAL AUDIT REPORT

Published July 2018 • 19 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Dyanavel XR through reportable promotional activity in 2017 and how does this compare to its peer set in the ADHD market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Tris’s depth of coverage vary within key specialties (e.g., Pediatric Medicine and Psychiatry) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Dyanavel XR throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Dyanavel XR in 2017?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available – covering payments to more than 975,000 U.S. healthcare professionals.
• Over 9,500 paid interactions across 4,600 physicians made on behalf of Dyanavel XR were carefully examined to support our analysis. In addition, interaction data from 7 peer products (e.g. Adzenys XR, Aptensio XR, Evekeo, Mydayis, QuilliChew ER, Quillivant XR, and Vyvanse ) was leveraged to provide benchmarking and market insights.